Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 70.00 | |
5 mg | In stock | $ 172.00 | |
10 mg | In stock | $ 278.00 | |
25 mg | In stock | $ 513.00 | |
50 mg | In stock | $ 747.00 | |
100 mg | In stock | $ 1,050.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 189.00 |
Description | Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively). |
Targets&IC50 | IDH1 (R132H):21.2 nM (IC50), IDH1 (R132C):114 nM (IC50) |
In vitro | Olutasidenib is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 (> 20 μM) and IDH2 mutants (R172K and R140Q: both > 20 μM). Olutasidenib effectively suppresses 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), displaying Olutasidenib (FT-2102) could be efficacious against most IDH1-R132 mutant-expressing tumors [2]. |
In vivo | In HCT116-IDH1-R132H/+ xenograft bearing female BALB/c Nude mice, Olutasidenib (three oral doses (12.5, 25, and 50 mg/kg) in 12-hour intervals) shows effective anti-tumor activity [2]. |
Synonyms | FT-2102 |
Molecular Weight | 354.79 |
Formula | C18H15ClN4O2 |
CAS No. | 1887014-12-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 122 mg/mL (343.87 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olutasidenib 1887014-12-1 Metabolism Dehydrogenase Isocitrate Dehydrogenase (IDH) mutant FT2102 FT 2102 inhibit 2-HG FT-2102 Inhibitor inhibitor